BURNABY, British Columbia--(BUSINESS WIRE)--ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes..

不列颠哥伦比亚省伯纳比市——（商业新闻短讯）——ARTMS Inc.（ARTMS）很高兴地宣布，Telix Pharmaceuticals Limited（Telix）的收购已经完成。此次收购通过对关键同位素的生产提供更高水平的供应链和监管控制，进一步加强了Telix供应链和制造业的垂直整合。

ARTMS will support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes for Telix’s portfolio of products, such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients.

ARTMS将为Telix的产品组合（如锆-89（89Zr）、镓-68（68Ga）、锝-99m（99mTc）和铜-64（64Cu））支持商业上重要的医用同位素的高效、大规模和经济高效的生产，并将继续与其他放射性制药公司合作，以确保这些关键同位素可根据患者的需求提供。

In addition, ARTMS’ portfolio of advanced cyclotron technologies has immediate application and differentiation for Telix in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At)..

此外，ARTMS的先进回旋加速器技术组合在Telix生产未来商业上重要的α发射治疗同位素（包括锕-225（225Ac）和阿斯汀-211（211At））方面具有直接的应用和区别。

The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc. After that project was successfully completed, the innovation continued and resulted in a full suite of PET products. In 2017, ARTMS Inc. was formed with support and seed funding from Quark Venture, through their Global Health Sciences Fund (GHS) and founding institutions TRIUMF, BC Cancer, Lawson Health Research Institute and the Center for Probe Development.

ARTMS的历史植根于加拿大政府资助的一个项目，该项目专注于99mTc的固体目标生产。该项目成功完成后，创新继续进行，产生了全套宠物产品。2017年，ARTMS Inc.在Quark Venture的支持和种子资助下，通过其全球健康科学基金（GHS）和创始机构TRIUMF，BC癌症，劳森健康研究所和探针开发中心成立。

In May of 2020, ARTMS completed a $20M USD Series A fundraising that included GHS and welcomed Deerfield Management to the ARTMS family. In the subsequent years ARTMS has played a critical role in alternative production of medical isotopes with a focus on accelerating the production capabilities of the world’s most commonly installed cyclotrons.

2020年5月，ARTMS完成了2000万美元的a系列筹款，其中包括GHS，并欢迎ARTMS家族的Deerfield管理层。在随后的几年中，ARTMS在医用同位素的替代生产中发挥了关键作用，重点是加速世界上最常安装的回旋加速器的生产能力。

The collaboration between ARTMS’ unparalleled team, its investors and founding members has resulted in a truly differentiated organization..

ARTMS无与伦比的团队、投资者和创始成员之间的合作造就了一个真正与众不同的组织。

Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix.

在与Telix收购相关的谈判和尽职调查过程中，Solomon Partners Securities LLC担任财务顾问，Norton Rose Fulbright Canada LLP担任ARTMS的法律顾问。

About ARTMS,

关于ARTMS，

Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain.

ARTMS Inc.位于加拿大不列颠哥伦比亚省伯纳比，是开发新技术和产品的全球领导者，这些新技术和产品能够高质量、高产量地生产世界上最常用的诊断成像同位素。ARTMS的旗舰产品QUANTM辐照系统（QISTM）能够使用药物分销商和医院医疗回旋加速器分散、经济高效地大规模生产重要的医用同位素，如镓-68（68Ga）、锆-89（89Zr）、锝-99m（99mTc）和铜-64（64Cu），使用户能够控制其供应链。

ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry..

ARTMS在全球范围内将这些屡获殊荣的加拿大专利发明商业化，并有望彻底改变核医学行业。

For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter/X @ARTMS_Inc/X and LinkedIn and visit http://www.artms.ca/

有关QUANTM辐照系统™和ARTMS的更多信息，请在推特/X@ARTMS\u Inc/X和LinkedIn上关注我们，并访问http://www.artms.ca/

About Telix Pharmaceuticals Limited

关于Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan.

Telix是一家生物制药公司，专注于诊断和治疗放射性药物及相关医疗设备的开发和商业化。Telix总部位于澳大利亚墨尔本，在美国、欧洲（比利时和瑞士）和日本开展国际业务。

Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX)..

Telix正在开发临床和商业阶段产品组合，旨在解决肿瘤学和罕见疾病中未满足的重大医疗需求。Telix在澳大利亚证券交易所（ASX:TLX）上市。

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

有关Telix的更多信息，请访问www.telixparma.com，包括最新股价的详细信息、向ASX发布的公告、投资者和分析师的演示、新闻稿、活动细节以及其他可能感兴趣的出版物。您也可以在X和LinkedIn上关注Telix。